Sintx Technologies Management

Management criteria checks 2/4

Sintx Technologies' CEO is B. Bal, appointed in Oct 2014, has a tenure of 9.58 years. total yearly compensation is $536.95K, comprised of 76.9% salary and 23.1% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $5.24. The average tenure of the management team and the board of directors is 9 years and 10 years respectively.

Key information

B. Bal

Chief executive officer

US$537.0k

Total compensation

CEO salary percentage	76.9%
CEO tenure	9.6yrs
CEO ownership	0.0001%
Management average tenure	9yrs
Board average tenure	10yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has B. Bal's remuneration changed compared to Sintx Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$537k	US$413k	-US$8m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$512k	US$400k	-US$16m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$483k	US$400k	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$487k	US$415k	-US$17m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$401k	US$400k	-US$7m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$22m
Dec 31 2018	US$412k	US$400k	-US$24m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$482k	US$400k	-US$6m

Compensation vs Market: B.'s total compensation ($USD536.95K) is above average for companies of similar size in the UK market ($USD347.26K).

Compensation vs Earnings: B.'s compensation has increased whilst the company is unprofitable.

CEO

B. Bal (61 yo)

9.6yrs

Tenure

US$536,951

Compensation

Dr. B. Sonny Bal, M.D. J.D. MBA, PhD, has been the Chief Executive Officer and President of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since October 2014 and its Chairman since August...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
B. Bal	CEO, President	9.6yrs	US$536.95k	0.00011% $ 5.2
David O'Brien	Executive VP & COO	9yrs	US$483.60k	0.00053% $ 25.2
Michael Marcroft	Vice President of Sales & Marketing	1.3yrs	no data	no data
Gina Moss	Director of Operations	no data	no data	no data

9.0yrs

Average Tenure

Experienced Management: 0A8S's management team is seasoned and experienced (9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
B. Bal	CEO, President	12.3yrs	US$536.95k	0.00011% $ 5.2
David Truetzel	Independent Director	13.7yrs	US$124.21k	0% $ 0
Erik Stookey	Independent Director	9.6yrs	US$43.43k	0% $ 0
Jeffrey White	Independent Director	10.3yrs	US$43.43k	no data
Mark Froimson	Independent Director	5.3yrs	US$43.18k	0% $ 0
Giuseppe Pezzotti	Member of Scientific Advisory Board	8.7yrs	no data	no data

10.0yrs

Average Tenure

62yo

Average Age

Experienced Board: 0A8S's board of directors are considered experienced (10 years average tenure).

Sintx Technologies Management

Management criteria checks 2/4

Key information

Recent management updates

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

Insufficient new directors

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Insufficient new directors

Insufficient new directors

Recent updates

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age